HYP-6589 / Huiyu Pharma - LARVOL DELTA

A phase I/II study evaluating HYP-6589 monotherapy for advanced solid tumors versus combination therapy with osimertinib for patients with advanced NSCLC targeting driver genes. (clinicaltrials.gov) - P1/2 | N=88 | Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd | Phase classification: P1 ➔ P1/2 | N=16 ➔ 88

Enrollment change • Monotherapy • Phase classification • Hepatocellular Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes (clinicaltrials.gov) - P1/2 | N=115 | Recruiting | Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd | Trial completion date: Jul 2026 ➔ Apr 2028 | Trial primary completion date: Jul 2026 ➔ Apr 2028

Monotherapy • Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor